Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTaieb, Julien
dc.contributor.authorPrager, Gerald W
dc.contributor.authorMelisi, Davide
dc.contributor.authorWestphalen, C Benedikt
dc.contributor.authorD'Esquermes, Nathalie
dc.contributor.authorFerreras, Anabel
dc.contributor.authorMacarulla Mercadé, Teresa
dc.date.accessioned2021-10-22T05:44:42Z
dc.date.available2021-10-22T05:44:42Z
dc.date.issued2020-01-20
dc.identifier.citationTaieb J, Prager GW, Melisi D, Westphalen CB, D’Esquermes N, Ferreras A, et al. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020 Jan 20;5:e000587.
dc.identifier.issn2059-7029
dc.identifier.urihttp://hdl.handle.net/11351/6435
dc.descriptionWestern Europe; Gemcitabine; Pancreatic cancer
dc.description.abstractBackground Treatment of metastatic pancreatic adenocarcinoma (mPAC) relies on chemotherapeutic regimens. We investigated patterns of first-line and second-line treatment choices, their geographical variation between European countries, and alignment with current European recommendations. Methods This retrospective, observational chart review study was conducted between July 2014 and January 2016. Physicians were recruited from nine European countries. Patient data were collected in electronic patient record forms (PRFs) by physicians managing patients with mPAC. Patients with a current mPAC diagnosis aged ≥18 years old who had completed first-line therapy during the study period were included. Results Participating physicians (n=225) completed 2565 PRFs. The vast majority of PRFs were from France, Germany, Italy, Spain and the UK. Most patients (86.6%) had stage IV disease at diagnosis. The most common first-line treatments were FOLFIRINOX (5-fluorouracil, leucovorin/folinic acid, irinotecan and oxaliplatin) (35.6%), gemcitabine+nab-paclitaxel (25.7%) and gemcitabine monotherapy (20.5%). Physicians in France and the UK prescribed FOLFIRINOX more frequently than gemcitabine+nab-paclitaxel. Gemcitabine-based therapies were more widely used at second-line, although 5-fluorouracil-based therapies were preferred in Italy and Spain, where gemcitabine-based treatments were more frequently selected for first-line. For patients receiving first-line modified FOLFIRINOX, second-line gemcitabine monotherapy was preferred in the overall population (45.9%). Conclusion Although treatment choices for patients with mPAC varied between countries, they align with current European guidelines. Factors including drug availability, reimbursement, patient characteristics, physician preference and prior first-line therapy affect treatment choices. Approved, recommended therapies for patients who progress following first-line treatment are lacking. These findings may influence the development of effective treatment plans, potentially improving future patient outcomes.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesESMO Open;5
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPàncrees - Càncer - Quimioteràpia
dc.subjectAdenocarcinoma - Quimioteràpia
dc.subject.meshPancreatic Neoplasms
dc.subject.meshAdenocarcinoma
dc.subject.mesh/drug therapy
dc.titleFirst-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/esmoopen-2019-000587
dc.subject.decsneoplasias pancreáticas
dc.subject.decsadenocarcinoma
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1136/esmoopen-2019-000587
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Taieb J] Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Sorbonne Paris Cité, Université Paris Descartes, Paris, France. [Prager GW] Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. [Melisi D] Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli Studi di Verona, Verona, Veneto, Italy. [Westphalen CB] Department of Medicine III and Comprehensive Cancer Center Munich, University Hospital LMU Munich, Munich, Germany. [D'Esquermes N, Ferreras A] Genactis SAS, Mougins, France. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid31958291
dc.identifier.wos000527764500006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record